ER negative

About

Biomarker Type: Protein expression

Present: True

Marker: Estrogen receptor (ER)

Unit: status

Equality: =

Value: Negative


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) HSE (4) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
EMA (1) FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab
EMA (1) FDA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine, Pembrolizumab
EMA (1) FDA (1) HSE (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Pembrolizumab
EMA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Nab-paclitaxel, Pembrolizumab
EMA (1) HSE (1) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel
HSE (2) ER negative Invasive Breast Carcinoma Fulvestrant
HSE (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine